Atossa Genetics stock hits 52-week low at $0.75

In a challenging market environment, Atossa Genetics Inc . (NASDAQ:ATOS) stock has touched a 52-week low, reaching a price level of $0.75. This latest dip underscores a period of volatility for the biopharmaceutical company, which has seen its shares struggle to gain momentum over the past year. With a beta of 1.27, the stock shows higher volatility than the broader market, though InvestingPro data reveals strong liquidity with a current ratio of 13.3. Despite the broader market’s fluctuations, Atossa Genetics has experienced a relatively modest 1-year change in its stock value, with a decrease of just -0.16%. Investors are closely monitoring the company’s performance, as it navigates through the biotech industry’s dynamic landscape, looking for signs of potential recovery or further decline. With analyst price targets ranging from $4 to $7 and two analysts recently revising earnings upward, InvestingPro subscribers can access 8 additional key insights about ATOS’s financial health and growth prospects.

In other recent news, Atossa Therapeutics has encountered a challenge with its ’334 patent deemed unpatentable by the Patent Trial and Appeal Board (PTAB). However, the company’s current clinical formulations remain unaffected, and it plans to file a new Continuation Patent Application. Atossa has also secured a new patent, U.S. Patent No. 12,201,591, covering sustained release compositions of endoxifen, a key compound in its drug development pipeline.

Atossa Therapeutics has reported significant advancements in their clinical programs for breast cancer treatment and prevention. The company completed the KARISMA-Endoxifen Phase 2 Study, which showed significant reductions in mammographic breast density, a risk factor for breast cancer. Further progress was made with the EVANGELINE trial, a phase 2 non-inferiority study, and two I-SPY 2 studies, all showing promising preliminary data.

Atossa Therapeutics has also strengthened its intellectual property portfolio with two new U.S. patents for (Z)-endoxifen. In response to these developments, H.C. Wainwright upgraded the stock price target for Atossa from $6.00 to $7.00, maintaining a Buy rating.

Additionally, Atossa has launched a clinical trial in collaboration with Quantum (NASDAQ:QMCO) Leap Healthcare Collaborative, testing a combination of (Z)-endoxifen and Eli Lilly (NYSE:LLY)’s abemaciclib. The outcomes of this trial are expected in 2026. These are the recent developments at Atossa Therapeutics.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.